Friday, September 29, 2023
Friday, September 29, 2023

Contact us 561.316.3330

Cellmyx Announces FDA 510(k) Clearance for intelliFat® BOD™ (Ref.# K210528)

Cellmyx, the authority on autologous adipose grafting and transfer, and a leader in medical technologies for orthopedic physicians, pain management and regenerative medicine, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for intelliFat® BOD™ (Ref.# K210528). The most advanced, quickest and easiest, single use kit for macro, micro, and nano fat tissue harvesting, processing, and transfer.

Cellmyx notes U.S. regulators have cleared the way for this groundbreaking new medical appliance and technology for use in orthopedic, plastic, and cosmetic surgery procedures. intelliFat® BOD™ successfully uses a patient’s own body fat, clinically referred to as adipose tissue, to aid in patient recovery and healing.

In some cases, intelliFat® BOD™ is used in conjunction with traditional orthopedic surgery to further advance patient outcomes. intelliFat® BOD™ is particularly attractive to physicians because it’s compliant with the latest FDA guidelines, preserving cellular and tissue micro-architecture of adipose, eliminating residual oil emulsion and blood, thereby providing a tissue byproduct that is minimally manipulated in accordance with FDA guidelines for Human Cell and Tissue Products.

Kits are sterile, and disposable, and contain a full suite of proprietary and stand-alone components to harvest, process, and transfer autologous adipose tissue for use as an alternative, and/or as an adjunct, to surgery for filling soft tissue defects and promoting healing in orthopedics, plastic, and cosmetic surgery, and a multitude of other surgical procedures and specialties.

Physicians feel empowered. They have the assets they need right at their fingertips to perform this revolutionary procedure without incising, stitching, or scarring the patient. intelliFat® BOD™ streamlines procedure times to under 30 minutes with its patented and unparalleled harvesting, processing, and transfer system. Patients experience no discomfort or downtime during or post-procedure and may return to normal social activities immediately with clearance from their provider.

According to Associate Clinical Professor of Medicine, University of Connecticut School of Medicine, Fellow of the American Osteopathic Academy of Sports Medicine, and Board Certified in Sports Medicine & Regenerative Medicine Dr. Paul D. Tortland, D.O. FAOASM, RSMK:

“I began performing autologous fat derived treatments for orthopedic regenerative medicine in 2009, the first physician in New England, and among the earliest in the country. Over the years I’ve trialed most commercially available systems to harvest and prepare adipose for injection. I have found these systems are cumbersome to use, time-consuming, or produce suboptimal product for injection. But with intelliFat® BOD™ Cellmyx hit the mark. Their kit is elegantly simple, fast and easy to use, and produces a superlative final product that’s easy to inject. Most importantly, I’m seeing outstanding clinical results.”

The intelliFat® 510(k) specifically includes procedures for neurosurgery, gastrointestinal and affiliated organ surgery, urological surgery, plastic, cosmetic, and reconstructive surgery, general surgery, orthopedic surgery, gynecological surgery, laparoscopic surgery, arthroscopic surgery, and thoracic surgery.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy